Bucillamine - Revive Therapeutics

Drug Profile

Bucillamine - Revive Therapeutics

Alternative Names: REV-002; REV-004; REV-005

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Revive Therapeutics
  • Class Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Chelating agents; Immunomodulators; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystinuria; Gout
  • Phase I Hepatolenticular degeneration

Most Recent Events

  • 12 Oct 2017 Chemical structure information added
  • 01 Mar 2017 Phase-II clinical trials in Cystinuria in USA (PO) (NCT02942420)
  • 06 Jul 2016 The US FDA accepts IND application for bucillamine in Cystinuria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top